Powering Liquid Biopsies with High-Quality Nucleic Acid
Mag-Bind® cfDNA kits help unlock actionable insights
from every sample—liquid or solid.
Mag-Bind® cfDNA Purification Kits from Omega Bio-tek
Modern precision medicine depends on high-quality nucleic acids—especially when samples are limited, degraded, or precious. Working with circulating tumor DNA (ctDNA) from plasma, Mag-Bind® magnetic bead purification kits deliver the consistency, sensitivity, and scalability required for today’s molecular diagnostics and translational research.
- extract cfDNA from up to 10 mL Plasma or Serum
- elute to as little as 50 µL
Built for All Workflows
Mag-Bind kits are designed for manual, semi-automated, and fully automated workflows, making them ideal for clinical labs, biobanks, and high-throughput research environments.
- Magnetic bead chemistry with scripts optimized for liquid handlers and magnetic processors
- Scalable from single samples to 96-well formats
- Reduce hands-on time, improve reproducibility, and confidently scale your biopsy workflows
Scientific Insights
Advancing Methylation Analysis with Reliable DNA Extraction
A recent study in Clinical Epigenetics (Nuttall et al., 2025) explored two ways of studying DNA methylation — an important marker that helps researchers understand how genes are turned on or off. The team compared a newer approach, enzymatic methylation sequencing (EM-seq), with the traditional bisulfite sequencing method, using a
Plasma cfDNA Methylation Profiling for Lung Cancer Detection Using Targeted EM-seq
This Scientific Reports study demonstrates how integrating cfDNA methylation patterns with fragment size analysis enables highly sensitive, non-invasive detection of lung cancer from plasma samples. By providing high-quality cfDNA isolation for targeted EM-seq workflows, Omega Bio-tek’s Mag-Bind® cfDNA Kit supports the precision and reliability required for advanced liquid biopsy diagnostics.
Ultra-Sensitive Cancer Monitoring from Plasma cfDNA Using Genome-Wide Sequencing
Early and accurate cancer monitoring remains a major clinical challenge, particularly when tumor burden is low or after surgical treatment. In the study Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring, researchers demonstrate how advances in whole-genome sequencing (WGS), paired with optimized cell-free DNA (cfDNA) extraction, can dramatically improve